

RESEARCH

Open Access

The impact of the genome-wide supported variant in the cyclin M2 gene on gray matter morphology in schizophrenia

Kazutaka Ohi^{1,2,3}, Ryota Hashimoto^{1,3,4*}, Hidenaga Yamamori^{1,3,5}, Yuka Yasuda^{1,3}, Michiko Fujimoto^{1,3}, Satomi Umeda-Yano⁵, Masaki Fukunaga⁶, Yoshiyuki Watanabe⁷, Masao Iwase¹, Hiroaki Kazui¹ and Masatoshi Takeda^{1,4}

Abstract

Background: Genome-wide significant associations of schizophrenia with eight SNPs in the *CNNM2*, *MIR137*, *PCGEM1*, *TRIM26*, *CSMD1*, *MMP16*, *NT5C2* and *CCDC68* genes have been identified in a recent mega-analysis of genome-wide association studies. To date, the role of these SNPs on gray matter (GM) volumes remains unclear.

Methods: After performing quality control for minor-allele frequency > 5% using a JPT HapMap sample and our sample, a genotyping call rate > 95% and Hardy-Weinberg equilibrium testing ($p > 0.01$), five of eight SNPs were eligible for analysis. We used a comprehensive voxel-based morphometry (VBM) technique to investigate the effects of these five SNPs on GM volumes between major-allele homozygotes and minor-allele carriers in Japanese patients with schizophrenia ($n = 173$) and healthy subjects ($n = 449$).

Results: The rs7914558 risk variant at *CNNM2* was associated with voxel-based GM volumes in the bilateral inferior frontal gyri (right $T = 4.96$, $p = 0.0088$, left $T = 4.66$, $p = 0.031$). These peak voxels, which were affected by the variant, existed in the orbital region of the inferior frontal gyri. Individuals with the risk G/G genotype of rs7914558 had smaller GM volumes in the bilateral inferior frontal gyri than carriers of the non-risk A-allele. Although several effects of the genotype and the genotype-diagnosis interaction of other SNPs on GM volumes were observed in the exploratory VBM analyses, these effects did not remain after the *FWE*-correction for multiple tests ($p > 0.05$).

Conclusions: Our findings suggest that the genetic variant in the *CNNM2* gene could be implicated in the pathogenesis of schizophrenia through the GM volumetric vulnerability of the orbital regions in the inferior frontal gyri.

Keywords: Schizophrenia, Genome-wide association study, Voxel-based morphometry, Cyclin M2 (*CNNM2*), Inferior frontal gyrus

Background

Schizophrenia is a common and complex psychiatric disorder with a lifetime risk of approximately 1%. This disorder has a strong genetic component; indeed, the estimated heritability is 81% [1]. Multiple genetic variants that have a small effect have been implicated in the pathogenesis of schizophrenia [2]. A genome-wide association study (GWAS) of single-nucleotide polymorphisms (SNPs) that

accesses tens of thousands of DNA samples from patients and controls can be a powerful tool for identifying common risk factors for complex diseases, such as schizophrenia. To date, GWASs on schizophrenia have identified several genome-wide significant associated variants located in the zinc finger protein 804A (*ZNF804A*), neurogranin (*NRGN*), transcription factor 4 (*TCF4*) genes and a major histocompatibility complex (MHC) region [3,4]. Subsequently, the influences of these SNPs in the genes on brain function and structure have been reported [5]. We have found that the genome-wide supported variant of the *NRGN* gene is associated with the brain morphology of the anterior cingulate cortex in patients with schizophrenia [6].

* Correspondence: hashimor@psy.med.osaka-u.ac.jp

¹Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan

³Core Research for Evolutionary Science and Technology of the Japan Science and Technology Agency, Saitama, Japan

Full list of author information is available at the end of the article

Recently, a combining analysis of a mega-analysis of GWAS data from 17 separate studies (9,394 cases and 12,462 controls) and the replication data (8,442 cases and 21,397 controls) of European ancestry have found genome-wide significant associations of schizophrenia with eight SNPs [rs7914558 (cyclin M2; *CNNM2*), rs1625579 (micro-RNA 137, *MIR137*), rs17662626 (*PCGEM1*, prostate-specific transcript, *PCGEM1*), rs2021722 (tripartite motif containing 26, *TRIM26*), rs10503253 (*CUB* and Sushi multiple domains 1, *CSMD1*), rs7004633 (matrix metalloproteinase 16, *MMP16*), rs11191580 (5'-nucleotidase, cytosolic II, *NT5C2*) and rs12966547 (coiled-coil domain containing 68, *CCDC68*)] from the five new (1p21.3, 2q32.3, 8p23.2, 8q21.3 and 10q24.32-q24.33) and two previously reported (6p21.32-p22.1 and 18q21.2) loci [7]. In studies exploring brain activation during a sentence completion task, individuals without the risk allele of the *MIR137* genotype had significantly greater activation in the posterior right medial frontal gyrus than at-risk individuals [8]. To our knowledge, however, no study has investigated the effects of these SNPs on gray matter (GM) volumes.

Many attempts have been made to minimize the clinical and genetic heterogeneity in studies of schizophrenia. One strategy for gene discovery uses neurobiological quantitative traits (QT) as intermediate phenotypes that reflect the underlying genetic vulnerability better than diagnostic categorization, such as schizophrenia [9,10]. This strategy has the potential to reduce clinical and genetic heterogeneity [11]. Structural GM volumes indicate substantial heritability rates ranging from moderate (40–70%) to high (70–95%) in the frontal and temporal brain regions [12,13]. Meta analyses of brain morphological studies in individuals with first-episode schizophrenia and neuroleptic naive schizophrenia as well as chronic patients with schizophrenia revealed reduction of GM volume in frontal, striato-limbic and temporal regions were present in the early stage of schizophrenia and were unrelated to the effects of neuroleptic treatment, chronicity and duration of illness [14–16]. Some studies have shown that abnormalities in GM volumes are intermediate phenotypes that bridge the gap between the genotype and diagnostic categorization [11,17]. Characterizing the functional effects of novel and poorly understood genetic variants on the intermediate phenotypes provides important insights into the neural mechanisms by which the variants increase the risk for schizophrenia [18]. Our research group has had a long-standing interest in the effects of genetic variants (i.e., *COMT*, *DISC1*, *PACAP*, *BDNF*, *APOE*, *AKT1* and *NRGN*) on brain structure in psychiatric disorders [6,19–24]. In this study, we examined the impact of the genome-wide supported variants on the GM volumes of patients with schizophrenia and healthy subjects. Using a comprehensive voxel-based morphometry

(VBM) technique, we tested the hypothesis that these risk variants would be associated with GM volumes.

Material and methods

Subjects

VBM analyses were conducted on 173 patients with schizophrenia (59.0% males, 102 males and 71 females, mean age \pm SD, range 36.0 \pm 12.3 years) and 449 healthy subjects (47.7% males, 214 males and 235 females, mean age \pm SD, range 35.4 \pm 12.8 years). All subjects were biologically unrelated within the second-degree of relationship and were of Japanese descent [25,26]. The subjects were excluded if they had neurological or medical conditions that could potentially affect the central nervous system, such as atypical headache, head trauma with loss of consciousness, chronic lung disease, kidney disease, chronic hepatic disease, thyroid disease, active cancer, cerebrovascular disease, epilepsy, seizures, substance-related disorders or mental retardation. Patients were recruited from the Osaka University Hospital. Each patient with schizophrenia had been diagnosed by at least two trained psychiatrists according to the criteria from the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* (DSM-IV) based on the Structured Clinical Interview for DSM-IV (SCID). Controls were recruited through local advertisements at Osaka University. Psychiatrically, medically and neurologically, the healthy subjects were evaluated using the non-patient version of the SCID to exclude individuals who had current or past contact with psychiatric services or who had received psychiatric medication. Current symptoms of schizophrenia were evaluated using the positive and negative syndrome scale (PANSS) [27]. Mean age and handedness did not differ significantly between the study group and the controls ($p > 0.38$), while the female ratio, years of education, estimated premorbid intelligence quotient (IQ) and total gray matter volumes were significantly lower in the patients with schizophrenia compared to the controls ($p < 0.016$) (Additional file 1: Table S1). All participants provided written informed consent after the study procedures had been fully explained. This study was performed in accordance with the World Medical Association's Declaration of Helsinki and was approved by the Research Ethical Committee of Osaka University.

SNP selection and SNP genotyping

We selected eight SNPs, rs7914558, rs1625579, rs17662626, rs2021722, rs10503253, rs7004633, rs11191580 and rs12966547, from a previous mega analysis of GWASs [7]. Of these eight SNPs, rs17662626 in the *PCGEM1* gene (2q32.3) was not polymorphic in the samples obtained from the HapMap Japanese in Tokyo (JPT) project. Because the other seven SNPs were common genetic variants in the HapMap JPT samples (minor allele frequency $> 5\%$), we focused on these SNPs. Venous blood was collected

from the subjects, and genomic DNA was extracted from whole blood according to standard procedures. These SNPs were genotyped using the TaqMan 5'-exonuclease allelic discrimination assay (Assay ID: rs7914558: C_31978821_10, rs1625579: C_8946584_20, rs2021722: C_11690541_10, rs10503253: C_1503810_20, rs7004633: C_29048976_10, rs11191580: C_31656012_10 and rs12966547: C_152930_10, Applied Biosystems, Foster City, CA, USA), as previously described [19,22]. Detailed information on the PCR conditions is available upon request. The genotyping call rates were 98.2% (rs7914558), 97.9% (rs1625579), 83.6% (rs2021722), 97.9% (rs10503253), 97.9% (rs7004633), 99.8% (rs11191580) and 97.6% (rs12966547). No deviation from the Hardy-Weinberg equilibrium (HWE) in the examined SNPs was detected in the patients or in controls ($p > 0.01$), with the exception of rs2021722. A significant deviation from HWE in the rs2021722 was found in both the patients ($p = 1.02 \times 10^{-17}$) and controls ($p = 2.05 \times 10^{-36}$) with a relative excess of CC homozygotes, TT homozygotes and undetermined subjects. According to the dbSNP database (National Center for Biotechnology Information), the SNP is shown as a tri-allelic variant with T/C/A. A number of genome-wide significant variants within MHC (6p21.32-p22.1), including rs2021722, have been identified [7]. However, the MHC region has been excluded from further analysis. Analyzing the region is difficult because of its high linkage disequilibrium (LD) and ethnic heterogeneity. Minor allele frequencies of rs1625579 were under 5% in our patients (3.2%) and controls (2.5%). Therefore, in this study, we excluded these SNPs rs2021722 and rs1625579 from the VBM analyses. Genotype and allele distributions for each SNP included in the VBM analyses between the patients with schizophrenia and the controls are shown in Table 1. All risk alleles were defined based on the previous GWAS [7]: rs7914558 (major G-allele), rs10503253 (minor A-allele), rs7004633 (minor G-allele), rs11191580 (major T-allele) and rs12966547 (minor G-allele). To increase the statistical power and decrease type I errors, homozygotes and the heterozygotes for the minor allele groups were combined and treated as minor-allele carriers. In this study, we contrasted

GM volumes between minor allele carriers and major allele homozygotes.

Magnetic resonance imaging procedure

All magnetic resonance imaging (MRI) studies were performed on a 1.5 T GE Signa EXCITE system. A three-dimensional volumetric acquisition of a T1-weighted gradient echo sequence produced a gapless series of 124 sagittal sections using a spoiled gradient recalled acquisition in the steady state (SPGR) sequence (TE/TR, 4.2/12.6 ms; flip angle, 15°; acquisition matrix, 256 × 256; 1NEX, FOV, 24 × 24 cm; slice thickness, 1.4 mm). Subjects with MRI abnormalities, such as infarcts, hemorrhages or brain tumors, were screened out prior to including this study as part of routine clinical diagnosis and treatment. Therefore, there were no gross abnormalities in any of the subjects. Each image was visually examined to eliminate images with motion or metal artifacts, and the anterior commissure-posterior commissure line was adjusted. The MRI images were processed using the VBM8 toolbox in Statistical Parametric Mapping 8 (SPM8; <http://www.fil.ion.ucl.ac.uk/spm/software/spm8/>) running on MATLAB R2013a (MathWorks, Natick, MA, USA) according to the VBM8-Toolbox Manual (<http://dbm.neuro.uni-jena.de/vbm8/VBM8-Manual.pdf>). The T1 images were normalized and segmented into GM, white matter (WM) and cerebrospinal fluid (CSF) using the VBM8 toolbox with defaults for the extended options. The modulated non-linear only (i.e., with no affine component) option was selected to create volumetric GM partitions. Finally, the images were smoothed with an 8-mm full-width, half-maximum isotropic Gaussian kernel.

Statistical analyses

In genetic association analysis, we performed power calculations using the Power Calculator for Two-Stage Association Studies (<http://www.sph.umich.edu/csg/abecasis/CaTS/>) [28]. The power estimate was based on an allele frequency of 0.53 at rs7914558, a prevalence of 0.01, an alpha level of 0.05, and assuming varying degrees of odds ratio using a multiplicative model. In brain morphological analyses, we performed power

Table 1 Genotype and allele distributions for each SNP between the patients with schizophrenia and healthy subjects

SNP IDs	Gene	Chr	Risk allele	Genotype frequencies						Risk allele frequencies		Allelic p value (χ^2)	OR (95% CI)
				+/+	+/-	-/-	+/+	+/-	-/-	SCZ	CON		
rs10503253	<i>CSMD1</i>	8p23.2	A/C	0.06	0.46	0.49	0.09	0.46	0.45	0.29	0.32	0.22 (1.5)	1.19 (0.90-1.56)
rs7004633	<i>MMP16</i>	8q21.3	G/A	0.03	0.37	0.60	0.06	0.36	0.57	0.21	0.25	0.24 (1.4)	1.20 (0.89-1.61)
rs7914558	<i>CNNM2</i>	10q24.32	G/A	0.23	0.53	0.24	0.29	0.49	0.22	0.49	0.53	0.23 (1.4)	1.16 (0.91-1.49)
rs11191580	<i>NT5C2</i>	10q24.33	T/C	0.49	0.42	0.09	0.50	0.42	0.07	0.70	0.72	0.55 (0.4)	1.09 (0.83-1.43)
rs12966547	<i>CCDC68</i>	18q21	G/A	0.15	0.44	0.41	0.17	0.44	0.39	0.37	0.39	0.54 (0.4)	1.09 (0.84-1.41)

Abbreviations: Chr Chromosome; SCZ patients with schizophrenia; CON healthy controls; +, risk allele; -, non-risk allele; OR odds ratio. For alleles, the first allele is the risk allele. All risk alleles are represented based on the previous GWAS [7].

calculations using the G*Power Version 3.1.5 [29]. The power estimate was based on an alpha level of 0.05, a power of 0.80 and assuming varying degrees of effect size using *t* tests. Standardized effect sizes were calculated using Cohen's *d* method (<http://www.uccs.edu/faculty/lbecker>).

Statistical analyses of the demographic variables were performed using PASW Statistics 18.0 software (SPSS Japan Inc., Tokyo, Japan). Based on the assumption that most of demographic variables, such as age and education years, were not fitted to a normality distribution with the Kolmogorov-Smirnov test ($p < 0.05$), differences in clinical characteristics between patients and controls or between genotypes were analyzed using the non-parametric Mann-Whitney *U*-test for continuous variables, such as age and years of education, and χ^2 tests for categorical variables, such as gender and handedness, as shown in Additional file 1: Table S1-S3. The presence of HWE was examined using the χ^2 test for goodness-of-fit via SNPalyze V5.1.1 Pro software (DYNACOM, Yokohama, Japan). The allelic distributions of each SNP between patients and controls were analyzed using χ^2 tests with the SNPalyze software. The significance levels for HWE and other statistical tests were set at two-tailed *p*-values, $p < 0.01$ and $p < 0.05$, respectively.

We performed a comprehensive exploratory whole brain search using the SPM8 statistical tools to examine the effects of the diagnosis, the genotype and their interaction of each SNP on GM volume in patients with schizophrenia and healthy subjects. As two-way ANOVA can simultaneously investigate these effects only in one model, these effects on GM volume were statistically assessed using a full factorial model for a 2×2 ANOVA with diagnosis (cases and controls) and genotype status (major-allele homozygotes and minor-allele carriers) as independent variables in SPM8. Gray matter volumes are correlated with age, and gender and years of education differed significantly between the patient and the control groups (Additional file 1: Table S1). Therefore, age, gender and years of education were included as covariates of no interest into the analyses to control for confounding variables. We contrasted GM volumes between the diagnostic groups (smaller volume region in patients with schizophrenia compared with healthy subjects), the genotype groups (smaller or larger volume region in minor-allele carriers relative to major-allele homozygotes) or the genotype-diagnosis interaction. Non-sphericity estimation was used. We applied a voxel-level height threshold of $p < 0.001$ (uncorrected for multiple comparisons) and clusters of more than 100 contiguous voxels were considered for the exploratory VBM analyses. And then we applied family-wise error (*FWE*) correction for multiple testing to avoid type I errors at the whole brain level. Eventually, the significance level was set at $p < 0.05$ (*FWE*_{corrected}). To obtain a cluster as large as possible, we extracted relative GM volumes from nominal

clusters in bilateral inferior frontal gyri at the lenient uncorrected threshold of $p < 0.001$ and cluster sizes > 100 . The extraction of these relative GM volumes were performed after including confounding factors such as age, sex and education years and modulated by total brain volumes in the VBM analyses. Anatomic localization was performed according to both the MNI coordinates and Talairach coordinates, which were obtained from M. Brett's transformations (<http://imaging.mrc-cbu.cam.ac.uk/imaging/MniTalairach>) and presented as Talairach coordinates.

Results

Our study size of 173 cases and 449 controls had sufficient power ($> 80\%$) to detect a genetic effect at odds ratio of 1.43 or greater for rs7914558 when the allele frequency was 0.53. Unfortunately, in our sample sizes, there was no allelic association with schizophrenia for any of the five SNPs [rs7914558 (*CNNM2*), rs10503253 (*CSMD1*), rs7004633 (*MMP16*), rs11191580 (*NT5C2*) and rs12966547 (*CCDC68*)] ($p > 0.22$, Table 1).

We investigated the effects of diagnosis (cases and controls), genotype (major-allele homozygotes and minor-allele carriers) and their interaction of five SNPs on GM volumes in a comprehensive exploratory VBM analysis. The effects of diagnosis between patients with schizophrenia and healthy subjects were found in all analyses of the present study ($p < 0.05$). Patients with schizophrenia showed smaller GM volumes compared with healthy subjects primarily in the frontal and temporal lobes, including the bilateral inferior frontal gyri, which was consistent with previous studies [14,30]. We found significant effects for the risk-allele homozygotes of rs7914558 on decreased GM volume in the bilateral inferior frontal gyri (right, $T = 4.96$, $p = 0.0088$; left, $T = 4.66$, $p = 0.031$), as shown in Table 2 and the regions based on the hot color map in Figure 1. To compare the effects of the genotype in both the patients with schizophrenia and healthy subjects, we extracted the means and SD for relative GM volumes from nominal clusters in bilateral inferior frontal gyri and the extracted GM volumes were shown in Figure 2 and Additional file 1: Table S2. The risk G-allele homozygotes of the *CNNM2* polymorphism had smaller GM volumes in the bilateral inferior frontal gyri compared to the non-risk allele carriers. The inferior frontal gyrus can be subdivided into three macroanatomical structures: the orbital (Brodmann area: BA47), opercular (BA44) and triangular (BA45) parts. In the present study, the peak GM regions affected by the *CNNM2* genotype existed in the orbital parts of the bilateral inferior frontal gyri. When the two genotype groups (G-allele homozygotes and A-allele carriers) were divided into three genotype groups (individuals with G/G genotype, G/A genotype and A/A genotype) and we performed an additional VBM analysis using a multiple regression model, the number of risk G-allele was significantly

Table 2 Effects of the *CNNM2* genotype and genotype-diagnosis interaction on GM volumes

Brain regions	R/L	BA	CS	<i>p</i> values (peak)		Talairach coordinates		
				<i>T</i>	<i>FWE</i>	<i>x</i>	<i>y</i>	<i>z</i>
Non-risk minor allele carrier > Risk major allele homozygote								
Inferior frontal Gyrus	R	11/47	1306	4.96	0.0088	22	31	-20
Inferior frontal Gyrus	L	47	437	4.66	0.031	-22	18	-22
Middle frontal Gyrus	L	11	667	4.33	0.11	-24	38	-18
Posterior cingulate	L	29	248	3.73	0.61	-7	-48	11
Non-risk minor allele carrier < Risk major allele homozygote								
no suprathreshold clusters								
Genotype-diagnosis interaction								
Superior temporal Gyrus	L	22	598	4.23	0.16	-46	-20	1

Abbreviations: R right; L left; BA Brodmann area; CS Cluster size; FWE family-wise error.

All regions shown have nominal association at a voxel-level height threshold of $p < 0.001$ and a minimum clusters extent of 100 voxels. Significant results ($FWE_{corrected} p < 0.05$) are shown in bold face.

related to smaller GM volumes of the right inferior frontal gyrus ($T = 4.67, p = 0.029$) but not the left inferior frontal gyrus ($T = 3.64, p = 0.70$) in total subjects.

As shown in Additional file 1: Table S1, patients with schizophrenia participated in this study were chronic and the symptoms were moderately stable. There was no difference in demographic information, such as duration of illness or PANSS scores, between risk G-allele homozygotes and non-risk A-allele carriers of rs7914558 ($p > 0.20$, Additional file 1: Table S3). However, to find whether there was potential clinical impact on our outcomes, we additionally investigated the genotype effect on GM volume

including chlorpromazine equivalent of total antipsychotics (mg/day), duration of illness or PANSS scores as covariant for VBM analyses only in patients. The genotype effect on these regions did not change even after controlling for these factors, suggesting that there was no potential clinical impact on our outcomes.

In the exploratory VBM analyses, we also found nominal effects of the risk-allele homozygotes of rs7914558 on decreased GM volume in the left middle frontal gyrus and the left posterior cingulate and a nominal genotype-diagnosis interaction with the GM volume in the left superior temporal gyrus ($p_{uncorrected} < 0.001$, Table 2).





Figure 1 Effects of the rs7914558 polymorphism at the *CNNM2* gene on GM volumes. There were effects of the risk-allele carriers of rs7914558 at *CNNM2* on decreased GM regions (red areas shown on the hot color map). There was no effect of the genotype on increased GM regions (blue area shown on the winter color map). Each color map shows the *t* values corresponding to the color in the figure.



Additionally, we found several marginal effects of genotypes and genotype-diagnosis interactions of other SNPs on GM volumes in the exploratory analyses ($uncorrected p < 0.001$, Additional file 1: Table S4 and Figure S1-S4). However, these effects of genotypes and genotype-diagnosis interactions on GM regions did not survive after the *FWE*-correction for multiple tests at the whole brain level ($p > 0.05$).

Discussion

To date, it remains unclear whether the genome-wide significant risk variants for schizophrenia in a mega-analysis of GWASs influenced GM volumes. This study is the first to identify the GM morphology associated with genome-wide risk variants using a comprehensive VBM technique. Of the five genetic variants investigated in this study, we found influences of the *CNNM2* genotype on the bilateral inferior frontal gyri at the whole brain level. GM volumes in the bilateral inferior frontal gyri, particularly the orbital region, in the risk G-allele homozygotes of *CNNM2* polymorphism were smaller than those observed in the non-risk allele carriers.

In genetic association analysis, our sample size had sufficient power ($>80\%$) to detect a genetic effect with odds ratio of 1.43 or greater for rs7914558. However, previous large GWAS has reported the genetic effect with low odds ratio of 1.10 for the SNP [7]. To detect such a small genetic effect, our sample size had insufficient power (12%),

and a large sample size of at least 3400 patients and 3400 controls is needed. On the other hand, in brain morphological analyses, our sample size had sufficient power ($>80\%$) to detect a genotype effect on GM volumes at medium effect size (Cohen's d) of 0.25 or greater. The observed effect sizes on the inferior frontal gyri were medium to large (0.29-1.00). These findings suggest that the genome-wide supported variant of schizophrenia had larger effect on GM volumes of the inferior frontal gyri than diagnostic status, and support that GM volumes abnormalities were prominent intermediate phenotypes bridging the gap between a susceptibility genetic variant and diagnostic categorization.

Rs7914558 is located in intron1 of the *CNNM2* gene (also known as *ACDP2*) on chromosome 10q24.32. The *CNNM2* gene spans 160.3 kb of genomic DNA and contains eight exons. This gene belongs to a member of the ancient conserved domain-containing protein family because the protein shares a domain conserved in a large number of species ranging from bacteria to human [31]. Members of this protein family contain a sequence motif that is present in the cyclin box, a cyclic nucleotide-monophosphate (cNMP)-binding domain. The *CNNM2* gene has a ubiquitous expression pattern in humans [31]. In particular, the level of *CNNM2* expression in the brain is moderate to high (<http://www.ebi.ac.uk/gxa/experiment/E-MTAB-37/ENSG00000148842>).

However, whether the expression level of this gene in the brains of patients with schizophrenia is lower or higher than that in healthy subjects is unknown. The encoded protein CNNM2 plays an important role in magnesium homeostasis by modulating Mg²⁺ concentration. The CNNM2 mRNA is upregulated when there is a deficiency of magnesium in the brain [32]. CNNM2 mediated Mg²⁺ -sensitive Na⁺ currents were blocked by increased extracellular Mg²⁺ concentrations [33]. We assessed the effect of the rs7914558 genotype on CNNM2 expression using bioinformatics data (<http://www.sanger.ac.uk/resources/software/genevar/>[34]) to examine whether the rs7914558 genotype might be an expression quantitative trait loci (eQTL). *In silico* analysis showed that the CNNM2 gene expression of the high-risk G genotype of rs7914558 was significantly lower than that of the non-risk genotype in the combined lymphoblast-derived HapMap CEU and YRI samples ($r = -.23$, $t = -2.59$, $p = 0.011$). The low expression of this gene resulted increased Mg²⁺ levels. Increased extracellular Mg²⁺ concentrations caused a decrease in the activity of the glutamate N-methyl-D-aspartate (NMDA) receptor [35]. These findings suggest that the CNNM2 gene may play an important role in the hypofunction of the NMDA receptor, which is implicated in the pathophysiology of schizophrenia.

The inferior frontal gyrus has a multifunctional role in human behavior, interpersonal interactions and communication [36]. The inferior frontal gyrus consists primarily of the heteromodal association neocortex, which is a major site of involvement in schizophrenia [37]. Several studies have reported that the relative GM in patients with schizophrenia was significantly reduced in the bilateral inferior frontal areas [38-40]. The inferior frontal gyrus can be subdivided into three macroanatomical parts: orbital, opercular and triangular. The orbital region is one of the major regions of the social brain that connects to the orbitofrontal cortex [41], while the opercular and triangular regions form Broca's area, which is an important region for speech-language production [42]. We found that the CNNM2 genotype affects brain volumes in the orbital regions of the inferior frontal gyri. Functionally, the orbital region is thought to be involved in the processing of empathy [36] and sentence comprehension [43,44] in the left hemisphere and decision-making cognition [41] and fine movement control [36] in the right hemisphere. Social functions are widely impaired in patients with schizophrenia [45-49]. It is still unclear whether and to what extent the effects of CNNM2 polymorphism on GM structure observed here might be associated with an increased risk for schizophrenia. We suggest that the CNNM2 variant may play a role in the social cognition and social functioning impairments noted in patients with schizophrenia through GM volumetric vulnerability of the orbital regions

of the inferior frontal gyri. Further research is needed to investigate how a possible relationship between the CNNM2 gene and hypofunction of the NMDA receptor would result in decreased GM volumes of the inferior frontal gyri.

There was no significant effect of the other four variants on any GM volumes. There are several possible reasons for the absence of an association. A false negative association cannot be excluded in our study because we applied a strict FWE correction for multiple comparisons at the whole brain level ($p < 0.05$). In the Additional file 1: Figure S1-S4, the regions shown at the more lenient uncorrected threshold of $p < 0.001$ may be helpful in further studies. Interestingly, many of the effects of these genome-wide significant variants at the lenient level involved decreased GM volumes, including the medial, middle and inferior frontal gyri. Reduced GM volumes in these regions have been repeatedly demonstrated in imaging studies of schizophrenia [14,30]. Another interpretation is that the effect of these variants was not sufficiently sensitive to the morphological vulnerability of the GM volumes. The effect of these variants may be preferable in identifying genotype-related vulnerability on other intermediate phenotypes, such as cognitive functions and personality traits. Therefore, further research is needed to confirm whether the effects of these variants could be related to the susceptibility of cognitive functioning.

There were several limitations to this study. Because a number of statistical analyses, including the effects of diagnosis, genotypes and their interaction on GM volumes, were performed, a correction for multiple testing should be considered. However, a consensus on how to correct such multiple testing on study combining brain imaging and genetics has not been reached in this research field. To control type I errors, we applied the strict FWE correction for all VBM analyses, while we did not perform any correction on the genetic modality. The existence of a false positive association cannot be excluded as an explanation for our results, although we were quite careful to match ethnicity and correct for multiple testing. Further investigations of other samples with much larger sample sizes and/or with different ethnicities and/or in relatives of those with schizophrenia are needed to confirm our findings. It is unclear whether our results are directly/indirectly linked to the CNNM2 polymorphism rs7914558, to other polymorphisms in high LD with this variant or to interactions between this variant and other variants. To determine whether rs7914558 is the most strongly associated variant for schizophrenia and brain structure in this gene, an extensive search for other functional variants at this locus is needed. Additionally, as with other risk variants for schizophrenia, clarifying the biological role of this SNP through *in vitro* and *in vivo* studies is important to improve the understanding of the pathophysiology of schizophrenia.

Conclusions

We found that a genome-wide supported variant of *CNNM2* could be associated with GM morphological vulnerability of the bilateral inferior frontal gyri. These results suggest that there may be possible deleterious effects of the risk G-allele at *CNNM2* in the inferior frontal gyri, which may, at least partially, represent the mechanism by which *CNNM2* increases the risk for schizophrenia. Further research will be needed to clarify the function of the risk *CNNM2* variant on the pathophysiology of schizophrenia.

Additional file

Additional file 1: Table S1. Demographic information for patients with schizophrenia and healthy subjects. **Table S2:** Effects of the rs7914558 genotype on extracted relative GM volumes of the bilateral inferior frontal gyri. **Table S3:** Demographic information for risk G-allele homozygotes and non-risk A-allele carriers of rs7914558. **Table S4:** Impacts of each genetic variant on GM volumes in the exploratory VBM analyses. **Figure S1:** Effects of the rs10503253 polymorphism (*CSMD1*) on GM volumes. **Figure S2:** Effects of the rs7004633 polymorphism (*MMP16*) on GM volumes. **Figure S3:** Effects of the rs11191580 polymorphism (*NTSC2*) on GM volumes. **Figure S4:** Effects of the rs12966547 polymorphism (*CCDC68*) on GM volumes.

Abbreviations

GM: Gray matter; VBM: Voxel-based morphometry; GWAS: Genome-wide association study; SNP: Single-nucleotide polymorphism; *CNNM2*: Cyclin M2; QT: Quantitative traits; DSM-IV: Diagnostic and statistical manual of mental disorders fourth edition; SCID: Structured clinical interview for DSM-IV; HWE: Hardy-Weinberg equilibrium; LD: Linkage disequilibrium; MRI: Magnetic resonance imaging; FWE: Family-wise error.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RH supervised the entire project, collected the data, wrote the manuscript, was critically involved in the design, analysis and interpretation of the data and was responsible for performing the literature review. KO was critically involved in the collection and analysis of the data, and contributed to the editing of the final manuscript and contributed intellectually to the interpretation of the data. HY and SU took part in genotyping. HY, YY, MF, MF, YW, MI, HK and MT contribute with sample collection and gave comments to the manuscript. All authors contributed to and have approved the final manuscript.

Acknowledgments

We would like to thank all of the individuals who participated in this study. This work was supported by research grants from the Japanese Ministry of Health, Labor and Welfare (H22-seishin-ippan-001); KAKENHI, 22390225-Grant-in-Aid for Scientific Research (B), 23659565-Grant-in-Aid for Challenging Exploratory Research and Grant-in-Aid for Scientific Research on Innovative Areas (Comprehensive Brain Science Network) from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT); CREST of JST; and the Japan Foundation for Neuroscience and Mental Health.

Author details

¹Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan. ²National Hospital Organization, Yamato Mental-Medical Center, Nara, Japan. ³Core Research for Evolutionary Science and Technology of the Japan Science and Technology Agency, Saitama, Japan. ⁴Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Osaka, Japan. ⁵Department of Molecular Neuropsychiatry, Osaka University Graduate School of Medicine, Osaka, Japan. ⁶Biofunctional Imaging, Immunology Frontier Research Center, Osaka University, Osaka, Japan. ⁷Department of Radiology, Osaka University Graduate School of Medicine, Osaka, Japan.

Received: 23 July 2013 Accepted: 21 October 2013

Published: 25 October 2013

References

1. Sullivan PF, Kendler KS, Neale MC: Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry* 2003, **60**:1187-1192.
2. Sun J, Kuo PH, Riley BP, Kendler KS, Zhao Z: Candidate genes for schizophrenia: a survey of association studies and gene ranking. *Am J Med Genet B Neuropsychiatr Genet* 2008, **147B**:1173-1181.
3. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J, Breuer R, Moller HJ, Giegling I, et al: Common variants conferring risk of schizophrenia. *Nature* 2009, **460**:744-747.
4. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini JL, Spencer CC, Howie B, Leung HT, Hartmann AM, Moller HJ, Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, et al: Identification of loci associated with schizophrenia by genome-wide association and follow-up. *Nat Genet* 2008, **40**:1053-1055.
5. Rose EJ, Donohoe G: Brain vs behavior: an effect size comparison of neuroimaging and cognitive studies of genetic risk for schizophrenia. *Schizophr Bull* 2013, **39**:518-526.
6. Ohi K, Hashimoto R, Yasuda Y, Nemoto K, Ohnishi T, Fukumoto M, Yamamori H, Umeda-Yano S, Okada T, Iwase M, Kazui H, Takeda M: Impact of the genome wide supported *NRGN* gene on anterior cingulate morphology in schizophrenia. *PLoS One* 2012, **7**:e29780.
7. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, et al: Genome-wide association study identifies five new schizophrenia loci. *Nat Genet* 2011, **43**:969-976.
8. Whalley HC, Papmeyer M, Romaniuk L, Sprooten E, Johnstone EC, Hall J, Lawrie SM, Evans KL, Blumberg HP, Sussmann JE, McIntosh AM: Impact of a microRNA MIR137 susceptibility variant on brain function in people at high genetic risk of schizophrenia or bipolar disorder. *Neuropsychopharmacology* 2012, **37**:2720-2729.
9. Meyer-Lindenberg A, Weinberger DR: Intermediate phenotypes and genetic mechanisms of psychiatric disorders. *Nat Rev Neurosci* 2006, **7**:818-827.
10. Tan HY, Callicott JH, Weinberger DR: Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer? *Mol Psychiatry* 2008, **13**:233-238.
11. Potkin SG, Turner JA, Guffanti G, Lakatos A, Torri F, Keator DB, Macciardi F: Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations. *Cogn Neuropsychiatry* 2009, **14**:391-418.
12. Kaymaz N, van Os J: Heritability of structural brain traits an endophenotype approach to deconstruct schizophrenia. *Int Rev Neurobiol* 2009, **89**:85-130.
13. Rijdsdijk FV, Viding E, De Brito S, Forgiarini M, Mechelli A, Jones AP, McCrory E: Heritable variations in gray matter concentration as a potential endophenotype for psychopathic traits. *Arch Gen Psychiatry* 2010, **67**:406-413.
14. Chan RC, Di X, McAlonan GM, Gong QY: Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. *Schizophr Bull* 2011, **37**:177-188.
15. Leung M, Cheung C, Yu K, Yip B, Sham P, Li Q, Chua S, McAlonan G: Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. *Schizophr Bull* 2011, **37**:199-211.
16. Ren W, Lui S, Deng W, Li F, Li M, Huang X, Wang Y, Li T, Sweeney JA, Gong Q: Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia. *Am J Psychiatry*. in press.

17. Goldman AL, Pezawas L, Mattay VS, Fischl B, Verchinski BA, Chen Q, Weinberger DR, Meyer-Lindenberg A: **Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability.** *Arch Gen Psychiatry* 2009, **66**:467–477.
18. Meyer-Lindenberg A: **Imaging genetics of schizophrenia.** *Dialogues Clin Neurosci* 2010, **12**:449–456.
19. Hashimoto R, Hashimoto H, Shintani N, Chiba S, Hattori S, Okada T, Nakajima M, Tanaka K, Kawagishi N, Nemoto K, Mori T, Ohnishi T, Noguchi H, Hori H, Suzuki T, Iwata N, Ozaki N, Nakabayashi T, Saitoh O, Kosuga A, Tatsumi M, Kamijima K, Weinberger DR, Kunugi H, Baba A: **Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia.** *Mol Psychiatry* 2007, **12**:1026–1032.
20. Hashimoto R, Hirata Y, Asada T, Yamashita F, Nemoto K, Mori T, Moriguchi Y, Kunugi H, Arima K, Ohnishi T: **Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease.** *Genes Brain Behav* 2009, **8**:43–52.
21. Hashimoto R, Moriguchi Y, Yamashita F, Mori T, Nemoto K, Okada T, Hori H, Noguchi H, Kunugi H, Ohnishi T: **Dose-dependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity.** *Neurosci Res* 2008, **61**:360–367.
22. Hashimoto R, Numakawa T, Ohnishi T, Kumamaru E, Yagasaki Y, Ishimoto T, Mori T, Nemoto K, Adachi N, Izumi A, Chiba S, Noguchi H, Suzuki T, Iwata N, Ozaki N, Taguchi T, Kamiya A, Kosuga A, Tatsumi M, Kamijima K, Weinberger DR, Sawa A, Kunugi H: **Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling.** *Hum Mol Genet* 2006, **15**:3024–3033.
23. Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Nemoto K, Ohnishi T, Yamamori H, Takahashi H, Iike N, Kamino K, Yoshida T, Azechi M, Ikezawa K, Tanimukai H, Tagami S, Morihara T, Okochi M, Tanaka T, Kudo T, Iwase M, Kazui H, Takeda M: **The AKT1 gene is associated with attention and brain morphology in schizophrenia.** *World J Biol Psychiatry* 2013, **14**:100–113.
24. Ohnishi T, Hashimoto R, Mori T, Nemoto K, Moriguchi Y, Iida H, Noguchi H, Nakabayashi T, Hori H, Ohmori M, Tsukue R, Anami K, Hirabayashi N, Harada S, Arima K, Saitoh O, Kunugi H: **The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia.** *Brain* 2006, **129**:399–410.
25. Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Iwase M, Iike N, Azechi M, Ikezawa K, Takaya M, Takahashi H, Yamamori H, Okochi T, Tanimukai H, Tagami S, Morihara T, Okochi M, Tanaka T, Kudo T, Kazui H, Iwata N, Takeda M: **The impact of a genome-wide supported psychosis variant in the ZNF804A gene on memory function in schizophrenia.** *Am J Med Genet B Neuropsychiatr Genet* 2010, **153B**:1459–1464.
26. Ohi K, Hashimoto R, Yasuda Y, Kiribayashi M, Iike N, Yoshida T, Azechi M, Ikezawa K, Takahashi H, Morihara T, Ishii R, Tagami S, Iwase M, Okochi M, Kamino K, Kazui H, Tanaka T, Kudo T, Takeda M: **TATA box-binding protein gene is associated with risk for schizophrenia, age at onset and prefrontal function.** *Genes Brain Behav* 2009, **8**:473–480.
27. Lindenmayer JP, Bernstein-Hyman R, Grochowski S: **A new five factor model of schizophrenia.** *Psychiatr Q* 1994, **65**:299–322.
28. Skol AD, Scott LJ, Abecasis GR, Boehnke M: **Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies.** *Nat Genet* 2006, **38**:209–213.
29. Faul F, Erdfelder E, Lang AG, Buchner A: **G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.** *Behav Res Methods* 2007, **39**:175–191.
30. Ellison-Wright I, Bullmore E: **Anatomy of bipolar disorder and schizophrenia: a meta-analysis.** *Schizophr Res* 2010, **117**:1–12.
31. Wang CY, Shi JD, Yang P, Kumar PG, Li QZ, Run QG, Su YC, Scott HS, Kao J, She JX: **Molecular cloning and characterization of a novel gene family of four ancient conserved domain proteins (ACDP).** *Gene* 2003, **306**:37–44.
32. Goytain A, Quamme GA: **Functional characterization of ACDP2 (ancient conserved domain protein), a divalent metal transporter.** *Physiol Genomics* 2005, **22**:382–389.
33. Stuijver M, Lainez S, Will C, Terry N, Gunzel D, Debaix H, Sommer K, Kopplin K, Thumfart J, Kampik NB, Querfeld U, Willnow TE, Nemecek V, Wagner CA, Hoenderop JG, Devuyt O, Knoers NV, Bindels RJ, Meij IC, Muller D: **CNNM2, encoding a basolateral protein required for renal Mg²⁺ handling, is mutated in dominant hypomagnesemia.** *Am J Hum Genet* 2011, **88**:333–343.
34. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, Montgomery S, Tavare S, Deloukas P, Dermitzakis ET: **Population genomics of human gene expression.** *Nat Genet* 2007, **39**:1217–1224.
35. Kochlamazashvili G, Bukalo O, Senkov O, Salmen B, Gerardy-Schahn R, Engel AK, Schachner M, Dityatev A: **Restoration of synaptic plasticity and learning in young and aged NCAM-deficient mice by enhancing neurotransmission mediated by GluN2A-containing NMDA receptors.** *J Neurosci* 2012, **32**:2263–2275.
36. Liakakis G, Nickel J, Seitz RJ: **Diversity of the inferior frontal gyrus—a meta-analysis of neuroimaging studies.** *Behav Brain Res* 2011, **225**:341–347.
37. Ross CA, Pearlson GD: **Schizophrenia, the heteromodal association neocortex and development: potential for a neurogenetic approach.** *Trends Neurosci* 1996, **19**:171–176.
38. Buchanan RW, Vladar K, Barta PE, Pearlson GD: **Structural evaluation of the prefrontal cortex in schizophrenia.** *Am J Psychiatry* 1998, **155**:1049–1055.
39. Yamasue H, Iwanami A, Hirayasu Y, Yamada H, Abe O, Kuroki N, Fukuda R, Tsujii K, Aoki S, Ohtomo K, Kato N, Kasai K: **Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study.** *Psychiatry Res* 2004, **131**:195–207.
40. Suzuki M, Nohara S, Hagino H, Kurokawa K, Yotsutsuji T, Kawasaki Y, Takahashi T, Matsui M, Watanabe N, Seto H, Kurachi M: **Regional changes in brain gray and white matter in patients with schizophrenia demonstrated with voxel-based analysis of MRI.** *Schizophr Res* 2002, **55**:41–54.
41. Rogers RD, Owen AM, Middleton HC, Williams EJ, Pickard JD, Sahakian BJ, Robbins TW: **Choosing between small, likely rewards and large, unlikely rewards activates inferior and orbital prefrontal cortex.** *J Neurosci* 1999, **19**:9029–9038.
42. Amunts K, Schleicher A, Burgel U, Mohlberg H, Uylings HB, Zilles K: **Broca's region revisited: cytoarchitecture and intersubject variability.** *J Comp Neurol* 1999, **412**:319–341.
43. Sakai KL, Nauchi A, Tatsuno Y, Hirano K, Muraishi Y, Kimura M, Bostwick M, Yusa N: **Distinct roles of left inferior frontal regions that explain individual differences in second language acquisition.** *Hum Brain Mapp* 2009, **30**:2440–2452.
44. Sakai KL: **Language acquisition and brain development.** *Science* 2005, **310**:815–819.
45. Bragado-Jimenez MD, Taylor PJ: **Empathy, schizophrenia and violence: a systematic review.** *Schizophr Res* 2012, **141**:83–90.
46. Sevy S, Burdick KE, Visweswarajah H, Abdelmessih S, Lukin M, Yechiam E, Bechara A: **Low gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders.** *Schizophr Res* 2007, **92**:74–84.
47. Billeke P, Aboitiz F: **Social cognition in schizophrenia: from social stimuli processing to social engagement.** *Front Psychiatry* 2013, **4**:4.
48. Kuperberg GR, Kreher DA, Ditman T: **What can event-related potentials tell us about language, and perhaps even thought, in schizophrenia?** *Int J Psychophysiol* 2010, **75**:66–76.
49. Vrtunski PB, Simpson DM, Weiss KM, Davis GC: **Abnormalities of fine motor control in schizophrenia.** *Psychiatry Res* 1986, **18**:275–284.

doi:10.1186/1744-9081-9-40

Cite this article as: Ohi et al.: The impact of the genome-wide supported variant in the cyclin M2 gene on gray matter morphology in schizophrenia. *Behavioral and Brain Functions* 2013 **9**:40.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

